Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis
about
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosisIntrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatmentsRole of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosisThe interaction affinity between vascular cell adhesion molecule-1 (VCAM-1) and very late antigen-4 (VLA-4) analyzed by quantitative FRETNatalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Therapeutic interference with leukocyte recirculation in multiple sclerosis.Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assayAntibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity.Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.Immunological Markers for PML Prediction in MS Patients Treated with NatalizumabTeriflunomide and its mechanism of action in multiple sclerosis.Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?Targeting cells in motion: migrating toward improved therapies.Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.Dendritic cells as therapeutic targets in neuroinflammation.Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis.Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study.To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis.Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.Innate Immunity in the CNS - A Focus on the Myeloid Cell
P2860
Q26770818-C637CD4B-3F12-4440-B585-FFB12800938FQ26851694-79FF2CF2-17FA-4F1B-8C5D-B769D248E352Q28082878-5AE0986B-D791-4CC9-8929-441F7E70A4E3Q28544741-9D3D3B0C-FCAC-4708-A848-D618BC57FA82Q30659100-02EC0B10-26EB-4FD8-AD69-A373A4741709Q30884219-0DEF06C9-4CDF-42F6-BAE3-97FDD598D059Q33745965-94455695-968A-40A4-BF8F-A608BC393662Q33758969-326A9BAE-9279-4E69-A35D-361F1BA813C9Q33975585-71658BDB-C749-4429-8523-670A9C7B51F7Q34818048-62B7B93D-E2E4-4C7A-B451-827B007074C5Q37730005-48A7ED51-1397-41EE-A63B-68A99F25E91AQ38078160-9650BC23-5F2A-4216-8835-9B34EDE49C57Q38098493-9ED7E13D-4CCB-4FAC-86C9-91F8AF3B8644Q38167347-B283C6A7-9860-4C1A-A417-E978ED9FC10BQ38771884-8C322859-D90C-48BF-91EF-5C7203AE8ED5Q40466907-AA474B37-3256-4AE9-8F53-3B79B71E425DQ42282094-60449357-0EAD-444C-90E1-4BEC0653A0E5Q47859915-5E569856-4AFE-4EC6-9DBC-C3010193B2A0Q49074970-C98E733E-7978-45A3-97B1-3CC26F8C8AD5Q49884884-62AB9099-EC3B-4623-9C84-4E2F5667D84EQ54207057-D9C73424-315A-4FC7-A3A6-865A0076BB1BQ57599442-0281E1D1-8EE4-4874-99CC-9AB2CBACA9A5
P2860
Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Long-term decrease in VLA-4 ex ...... tients with multiple sclerosis
@ast
Long-term decrease in VLA-4 ex ...... tients with multiple sclerosis
@en
Long-term decrease in VLA-4 ex ...... tients with multiple sclerosis
@nl
type
label
Long-term decrease in VLA-4 ex ...... tients with multiple sclerosis
@ast
Long-term decrease in VLA-4 ex ...... tients with multiple sclerosis
@en
Long-term decrease in VLA-4 ex ...... tients with multiple sclerosis
@nl
prefLabel
Long-term decrease in VLA-4 ex ...... tients with multiple sclerosis
@ast
Long-term decrease in VLA-4 ex ...... tients with multiple sclerosis
@en
Long-term decrease in VLA-4 ex ...... tients with multiple sclerosis
@nl
P2093
P2860
P1433
P1476
Long-term decrease in VLA-4 ex ...... tients with multiple sclerosis
@en
P2093
Bárbara Alonso
Clara de Andrés
Eduardo Fernández-Cruz
Juan Guzmán de Villoria
M Luisa Martínez
Roseta Teijeiro
Silvia Sánchez-Ramón
P2860
P304
P356
10.1371/JOURNAL.PONE.0034103
P407
P577
2012-01-01T00:00:00Z